Skip to main content

MolecularMD, Asterand Bioscience Form Biomarker Alliance

NEW YORK (GenomeWeb) – MolecularMD has partnered with Asterand Bioscience to provide its biopharma customers with an end-to-end workflow for biomarker and cancer drug target validation, and assay development, the companies announced today.

Under the terms of the deal, MolecularMD will access Asterand's human tissue procurement, characterization, and research services to assist with the development of custom clinical trial assays and companion diagnostic products for its clients. Specific details were not disclosed.

The alliance, MolecularMD President and CEO Dan Snyder said in a statement, "will help our broad client base accelerate their pipeline decisions and dramatically improve the efficiency of the clinical trial and commercialization workflow."

The Scan

Not Kept "Clean and Sanitary"

A Food and Drug Administration inspection uncovered problems with cross contamination at an Emergent BioSolutions facility, the Wall Street Journal reports.

Resumption Recommendation Expected

The Washington Post reports that US officials are expected to give the go-ahead to resume using Johnson & Johnson's SARS-CoV-2 vaccine.

Canada's New Budget on Science

Science writes that Canada's new budget includes funding for the life sciences, but not as much as hoped for investigator-driven research.

Nature Papers Examine Single-Cell, Multi-Omic SARS-CoV-2 Response; Flatfish Sequences; More

In Nature this week: single-cell, multi-omics analysis provides insight into COVID-19 pathogenesis, evolution of flatfish, and more.